Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: YES.

Zecca, Chiara; Gobbi, Claudio

Zecca, Chiara; Gobbi, Claudio.

Zecca C; Multiple Sclerosis Center, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland/Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.
Gobbi C; Multiple Sclerosis Center, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland/Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.

Mult Scler ; 28(8): 1173-1175, 2022 07.

Article in English | MEDLINE | ID: covidwho-1916842

Subject(s)

Antibodies, Monoclonal; Antineoplastic Agents; Antibodies, Monoclonal/therapeutic use; Antigens, CD20; Humans; Rituximab/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Monoclonal / Antineoplastic Agents Type of study: Prognostic study Limits: Humans Language: English Journal: Mult Scler Journal subject: Neurology Year: 2022 Document Type: Article Affiliation country: 13524585221088734

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google